{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-115943","form_type":"8-K","ticker":"NNVC","cik":"0001379006","company_name":"NANOVIRICIDES, INC.","filed_at":"2021-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.893107+00:00","generated_at":"2026-06-29T03:28:17.362967+00:00","sec_items":["1.01","5.02"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NanoViricides licenses coronavirus drug field from TheraCour; no upfront cash","bullets":["Exclusive worldwide license for coronavirus antiviral drugs; no upfront cash payment to TheraCour.","Milestone payments include up to 750,000 Series A preferred shares and up to $11M in cash tied to clinical development.","Royalty of 15% on net sales of licensed products; TheraCour retains manufacturing rights.","President Anil Diwan's employment extended to June 30, 2022 with $400K base salary and 10,204 Series A shares vesting quarterly."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-115943","json":"https://secwatch.observer/filing/0001104659-21-115943.json","markdown":"https://secwatch.observer/filing/0001104659-21-115943.md","text":"https://secwatch.observer/filing/0001104659-21-115943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379006/000110465921115943/0001104659-21-115943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379006/000110465921115943/tm2127721d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:28:17.362967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}